Johnson & Johnson
$274.40
+3.36 · +1.24% today
Market open · updated 12:45:29 PM ET
- High
- $277.72 7:15 AM
- Low
- $273.75 4:25 AM
Against the S&P 500 Price change through Oct 28, 2026
JNJ+30.97%
S&P 500+13.26%
JNJ+45.00%
S&P 500+12.41%
JNJ+86.15%
S&P 500+88.06%
JNJ+66.44%
S&P 500+68.51%
Key numbers
- Previous close
- $271.04
- Open
- $275.31
- Day's range
- $274.27 – $278.01
- 52-week range
- $185.12 – $281.07
- Volume
- 2.7 million
- Average volume
- 7.4 million
- Market value
- $660.6 billion
- Price to earnings
- 41.1last 12 months
- Earnings per share
- $6.58last 12 months
- Beta
- 0.23moves less than the market
- Dividend
- $5.28 a year · 1.95%
- 50-day average
- $265.45
- 200-day average
- $246.40
Wednesday, Jan 20, 2027, before the open.
Analyst price targets and the full financials are in the terminal.
Who Johnson & Johnson buys from and competes with From our value chain
Johnson & Johnson in the news
- HeadlineJohnson & Johnson (JNJ) Is Considered a Good Investment by Brokers: Is That True?Zacks Investment Research · October 29, 2026 at 10:31 AM ET
- HeadlineJohnson & Johnson: Strong Q3 Growth, But 2027 Could Test Its EarningsSeeking Alpha · October 29, 2026 at 3:40 AM ET
- Headline2 Safe S&P 500 Dividend Stocks Boomers Can Buy and Hold Forever24/7 Wall Street · October 26, 2026 at 8:45 AM ET
- HeadlineT-Bills Yield Up to 4.45%. Why Would Retirees Choose Dividend Stocks?24/7 Wall Street · October 25, 2026 at 4:00 PM ET
- HeadlineJohnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancerPRNewsWire · October 24, 2026 at 8:54 AM ET
- HeadlineNANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous MelanomaGlobeNewsWire · October 24, 2026 at 7:00 AM ET
- HeadlineJohnson & Johnson's prostate cancer drug shrinks tumors in early-stage trialReuters · October 24, 2026 at 4:18 AM ET
- HeadlineJ&J Stock Reclaims 50-Day SMA: Is it Time to Buy, Sell or Hold?Zacks Investment Research · October 23, 2026 at 10:41 AM ET
Earnings
Next report: Wednesday, Jan 20, 2027, before the open.
Congress trades in JNJ
4 purchases and 4 sales in the latest 8 filings.
| Member | Trade | Amount | Traded | Disclosed |
|---|---|---|---|---|
| Ro KhannaHouse · D-California | Purchase | $1,001 - $15,000 | Sep 25, 2026 | Oct 9, 2026 |
| Ro KhannaHouse · D-California | Purchase | $15,001 - $50,000 | Sep 4, 2026 | Oct 9, 2026 |
| Lloyd DoggettHouse · D-Texas | Purchase | $1,001 - $15,000 | Sep 8, 2026 | Oct 6, 2026 |
| Thomas KeanHouse · R-New Jersey | Sale | $1,001 - $15,000 | Aug 27, 2026 | Sep 14, 2026 |
| John BoozmanSenate · R-Arkansas | Sale | $1,001 - $15,000 | Aug 20, 2026 | Sep 11, 2026 |
| Ro KhannaHouse · D-California | Sale | $1,001 - $15,000 | Aug 7, 2026 | Sep 7, 2026 |
| Ro KhannaHouse · D-California | Purchase | $1,001 - $15,000 | Jul 2, 2026 | Aug 12, 2026 |
| Thomas KeanHouse · R-New Jersey | Sale | $1,001 - $15,000 | Jun 29, 2026 | Jul 16, 2026 |
Source: Periodic transaction reports filed with the House and the Senate · Members disclose ranges, not exact amounts, and may file weeks after the trade.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 141,700
- Headquarters
- New Brunswick, New Jersey
- Website
- jnj.com
- Listed
- Jan 2, 1962
More drug manufacturers - general stocks
The price refreshes every 15 seconds while the market is open and carries the time it was read. Company figures are updated each evening. Built from WiseView and market data and public filings. For information only, not investment advice.